New Drug Repurposing Platform Announced
Availability Targeted to Biotechnology and Pharmaceutical Companies
A new small satellite (CubeSat) platform has been introduced in a collaborative effort between Vector Space Biosciences, Oracle and NVIDIA.
"Without understanding how to protect and repair the human body during spaceflight, we simply won’t be establishing lunar bases or going to Mars anytime soon."
Kasian Franks, Vector Space Biosciences
The platform is powered by a biosciences lab, a CubeSat lab, and a language modeling/AI lab which includes an ensemble of small highly targeted biological language modeling and large biological language modeling (LLMs), generative AI, protein sequence matching, vector databases and advanced visualizations. This pipeline enables the development of countermeasures against diseases associated with stressors resulting from human spaceflight. Countermeasures not only protect humans in space but also double as new forms of precision medicine for all mankind.
Once a CubeSat is designed, developed, and launched, data is transmitted to ground stations in collaboration with Microsoft Azure Space. This data is augmented with current biomedical data and preprocessed for language modeling. Feature vectors are extracted from the trained models and are used to construct real-time hidden relationship networks between genes, proteins, diseases, drug compounds and other biochemicals.
Data generated from CubeSats in space is not only high-value, unique and powerful but also can enable new discoveries in the areas of drug discovery, development and design in addition to drug repurposing which has proven to be a vital area of discovery as shown by the recent example of Novo Nordisk’s Wegovy (semaglutide), a weight loss drug, which has been shown to help patients lose an average of 15% of their weight, also reduced incidence of heart attack, stroke or death from heart disease by 20%.
"Without understanding how to protect and repair the human body during spaceflight, we simply won’t be establishing lunar bases or going to Mars anytime soon," said Kasian Franks, Vector Space Biosciences founder and CEO. "However, if we focus on creating solutions in this area now, we can develop and repurpose new therapeutic applications in precision medicine that benefit all mankind, today. This is the focus of Vector Space Biosciences.”
Vector Space Biosciences trades under the cryptocurrency symbol SBIO and enables payments via its subsidiary, Vectorspace AI and its utility token, VXV.